ipharma 2 ltd
ipharma 2 ltd Company Information
Group Structure
View All
Industry
Dispensing chemist in specialised stores
Registered Address
2-3 hill side buildings, beeston road, leeds, LS11 6AY
Website
www.i-pharma.co.ukipharma 2 ltd Estimated Valuation
Pomanda estimates the enterprise value of IPHARMA 2 LTD at £529k based on a Turnover of £1.6m and 0.33x industry multiple (adjusted for size and gross margin).
ipharma 2 ltd Estimated Valuation
Pomanda estimates the enterprise value of IPHARMA 2 LTD at £0 based on an EBITDA of £-23.8k and a 3.93x industry multiple (adjusted for size and gross margin).
ipharma 2 ltd Estimated Valuation
Pomanda estimates the enterprise value of IPHARMA 2 LTD at £345.1k based on Net Assets of £165.3k and 2.09x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Ipharma 2 Ltd Overview
Ipharma 2 Ltd is a live company located in leeds, LS11 6AY with a Companies House number of 09016820. It operates in the dispensing chemist in specialised stores sector, SIC Code 47730. Founded in April 2014, it's largest shareholder is el-horeb limited with a 100% stake. Ipharma 2 Ltd is a established, small sized company, Pomanda has estimated its turnover at £1.6m with rapid growth in recent years.
Upgrade for unlimited company reports & a free credit check
Ipharma 2 Ltd Health Check
Pomanda's financial health check has awarded Ipharma 2 Ltd a 1.5 rating. We use a traffic light system to show it exceeds the industry average on 1 measures and has 6 areas for improvement. Company Health Check FAQs
1 Strong
3 Regular
6 Weak
Size
annual sales of £1.6m, make it smaller than the average company (£13.5m)
- Ipharma 2 Ltd
£13.5m - Industry AVG
Growth
3 year (CAGR) sales growth of 38%, show it is growing at a faster rate (7.6%)
- Ipharma 2 Ltd
7.6% - Industry AVG
Production
with a gross margin of 26.6%, this company has a comparable cost of product (31.8%)
- Ipharma 2 Ltd
31.8% - Industry AVG
Profitability
an operating margin of -1.5% make it less profitable than the average company (2.4%)
- Ipharma 2 Ltd
2.4% - Industry AVG
Employees
with 10 employees, this is below the industry average (74)
10 - Ipharma 2 Ltd
74 - Industry AVG
Pay Structure
on an average salary of £28.1k, the company has an equivalent pay structure (£28.1k)
- Ipharma 2 Ltd
£28.1k - Industry AVG
Efficiency
resulting in sales per employee of £160.1k, this is equally as efficient (£145.5k)
- Ipharma 2 Ltd
£145.5k - Industry AVG
Debtor Days
it gets paid by customers after 87 days, this is later than average (29 days)
- Ipharma 2 Ltd
29 days - Industry AVG
Creditor Days
its suppliers are paid after 0 days, this is quicker than average (60 days)
- Ipharma 2 Ltd
60 days - Industry AVG
Stock Days
There is insufficient data available for this Key Performance Indicator!
- Ipharma 2 Ltd
- - Industry AVG
Cash Balance
There is insufficient data available for this Key Performance Indicator!
- - Ipharma 2 Ltd
- - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 66%, this is a higher level of debt than the average (59.5%)
66% - Ipharma 2 Ltd
59.5% - Industry AVG
IPHARMA 2 LTD financials
Ipharma 2 Ltd's latest turnover from June 2024 is estimated at £1.6 million and the company has net assets of £165.3 thousand. According to their latest financial statements, Ipharma 2 Ltd has 10 employees and maintains cash reserves of 0 as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
| Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 | Jun 2019 | Jun 2018 | Jun 2017 | Jun 2016 | Jun 2015 | Jun 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | |||||||||||
| Other Income Or Grants | |||||||||||
| Cost Of Sales | |||||||||||
| Gross Profit | |||||||||||
| Admin Expenses | |||||||||||
| Operating Profit | |||||||||||
| Interest Payable | |||||||||||
| Interest Receivable | |||||||||||
| Pre-Tax Profit | |||||||||||
| Tax | |||||||||||
| Profit After Tax | |||||||||||
| Dividends Paid | |||||||||||
| Retained Profit | |||||||||||
| Employee Costs | |||||||||||
| Number Of Employees | 10 | 10 | 10 | 10 | 10 | 9 | 9 | 8 | |||
| EBITDA* |
* Earnings Before Interest, Tax, Depreciation and Amortisation
| Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 | Jun 2019 | Jun 2018 | Jun 2017 | Jun 2016 | Jun 2015 | Jun 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Tangible Assets | 100,108 | 111,137 | 20,926 | 26,158 | 32,698 | 36,583 | 42,113 | 51,357 | 28,496 | 32,800 | |
| Intangible Assets | 92,750 | 98,547 | 104,344 | ||||||||
| Investments & Other | |||||||||||
| Debtors (Due After 1 year) | |||||||||||
| Total Fixed Assets | 100,108 | 111,137 | 113,676 | 124,705 | 137,042 | 36,583 | 42,113 | 51,357 | 28,496 | 32,800 | |
| Stock & work in progress | 38,472 | 29,886 | 20,870 | 26,565 | 44,219 | 45,467 | 58,778 | 45,253 | |||
| Trade Debtors | 385,291 | 376,148 | 214,441 | 64,210 | 73,761 | 139,980 | 221,669 | ||||
| Group Debtors | |||||||||||
| Misc Debtors | 256,436 | 266,317 | 276,971 | 29,827 | 37,928 | 45,913 | |||||
| Cash | 347,474 | 165,084 | 82,965 | 1,488 | 73,411 | 87,232 | 22,077 | 24,919 | |||
| misc current assets | |||||||||||
| total current assets | 385,291 | 376,148 | 642,382 | 461,287 | 380,806 | 315,536 | 211,667 | 244,388 | 266,748 | 291,841 | |
| total assets | 485,399 | 487,285 | 756,058 | 585,992 | 517,848 | 352,119 | 253,780 | 295,745 | 295,244 | 324,641 | |
| Bank overdraft | |||||||||||
| Bank loan | |||||||||||
| Trade Creditors | 2,956 | 3,432 | 157,482 | 127,613 | 141,124 | 249,431 | 220,473 | 191,775 | 151,370 | 284,105 | |
| Group/Directors Accounts | 14,825 | 4,699 | 7,677 | ||||||||
| other short term finances | |||||||||||
| hp & lease commitments | |||||||||||
| other current liabilities | 47,507 | 24,422 | 22,591 | 16,037 | 22,318 | 72,504 | |||||
| total current liabilities | 2,956 | 3,432 | 219,814 | 156,734 | 171,392 | 283,886 | 236,510 | 214,093 | 223,874 | 284,105 | |
| loans | 27,948 | 307,946 | 319,061 | 270,000 | |||||||
| hp & lease commitments | |||||||||||
| Accruals and Deferred Income | |||||||||||
| other liabilities | 317,148 | 265,000 | 13,943 | ||||||||
| provisions | 37 | 45 | |||||||||
| total long term liabilities | 317,148 | 292,948 | 307,946 | 319,061 | 270,000 | 37 | 45 | 13,943 | |||
| total liabilities | 320,104 | 296,380 | 527,760 | 475,795 | 441,392 | 283,886 | 236,547 | 214,138 | 223,874 | 298,048 | |
| net assets | 165,295 | 190,905 | 228,298 | 110,197 | 76,456 | 68,233 | 17,233 | 81,607 | 71,370 | 26,593 | |
| total shareholders funds | 165,295 | 190,905 | 228,298 | 110,197 | 76,456 | 68,233 | 17,233 | 81,607 | 71,370 | 26,593 |
| Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 | Jun 2019 | Jun 2018 | Jun 2017 | Jun 2016 | Jun 2015 | Jun 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||||||
| Operating Profit | |||||||||||
| Depreciation | 5,232 | 6,540 | 8,726 | 8,030 | 9,244 | 5,129 | 5,904 | ||||
| Amortisation | 5,797 | 5,797 | 5,797 | ||||||||
| Tax | |||||||||||
| Stock | -38,472 | 8,586 | 9,016 | -5,695 | -17,654 | -1,248 | -13,311 | 13,525 | 45,253 | ||
| Debtors | 9,143 | 119,712 | -9,881 | -10,654 | 62,530 | 120,404 | -17,652 | -74,204 | -35,776 | 221,669 | |
| Creditors | -476 | -154,050 | 29,869 | -13,511 | -108,307 | 28,958 | 28,698 | 40,405 | -132,735 | 284,105 | |
| Accruals and Deferred Income | -47,507 | 23,085 | 1,831 | 22,591 | -16,037 | -6,281 | -50,186 | 72,504 | |||
| Deferred Taxes & Provisions | -37 | -8 | 45 | ||||||||
| Cash flow from operations | |||||||||||
| Investing Activities | |||||||||||
| capital expenditure | |||||||||||
| Change in Investments | |||||||||||
| cash flow from investments | |||||||||||
| Financing Activities | |||||||||||
| Bank loans | |||||||||||
| Group/Directors Accounts | -14,825 | 10,126 | -2,978 | 7,677 | |||||||
| Other Short Term Loans | |||||||||||
| Long term loans | -27,948 | -279,998 | -11,115 | 49,061 | 270,000 | ||||||
| Hire Purchase and Lease Commitments | |||||||||||
| other long term liabilities | 52,148 | 265,000 | -13,943 | 13,943 | |||||||
| share issue | |||||||||||
| interest | |||||||||||
| cash flow from financing | |||||||||||
| cash and cash equivalents | |||||||||||
| cash | -347,474 | 182,390 | 82,119 | 81,477 | -71,923 | -13,821 | 65,155 | -2,842 | 24,919 | ||
| overdraft | |||||||||||
| change in cash | -347,474 | 182,390 | 82,119 | 81,477 | -71,923 | -13,821 | 65,155 | -2,842 | 24,919 |
ipharma 2 ltd Credit Report and Business Information
Ipharma 2 Ltd Competitor Analysis
Perform a competitor analysis for ipharma 2 ltd by selecting its closest rivals, whether from the WHOLESALE AND RETAIL TRADE; REPAIR OF MOTOR VEHICLES AND MOTORCYCLES sector, other small companies, companies in LS11 area or any other competitors across 12 key performance metrics.
ipharma 2 ltd Ownership
IPHARMA 2 LTD group structure
Ipharma 2 Ltd has no subsidiary companies.
Ultimate parent company
IPHARMA 2 LTD
09016820
ipharma 2 ltd directors
Ipharma 2 Ltd currently has 1 director, Mr Michael Olawepo serving since Nov 2018.
| officer | country | age | start | end | role |
|---|---|---|---|---|---|
| Mr Michael Olawepo | England | 52 years | Nov 2018 | - | Director |
P&L
June 2024turnover
1.6m
-7%
operating profit
-23.8k
0%
gross margin
26.6%
-2.15%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
June 2024net assets
165.3k
-0.13%
total assets
485.4k
0%
cash
0
0%
net assets
Total assets minus all liabilities
Similar Companies
ipharma 2 ltd company details
company number
09016820
Type
Private limited with Share Capital
industry
47730 - Dispensing chemist in specialised stores
incorporation date
April 2014
age
11
incorporated
UK
ultimate parent company
accounts
Micro-Entity Accounts
last accounts submitted
June 2024
previous names
N/A
accountant
-
auditor
-
address
2-3 hill side buildings, beeston road, leeds, LS11 6AY
Bank
-
Legal Advisor
-
ipharma 2 ltd Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We found 3 charges/mortgages relating to ipharma 2 ltd. Currently there are 3 open charges and 0 have been satisfied in the past.
ipharma 2 ltd Capital Raised & Share Issues BETA
When a company issues new shares, e.g. to new investors following a funding round, it is required to notify Companies House within one month of making an allotment of shares.
Click to start generating capital raising & share issue transactions for IPHARMA 2 LTD. This can take several minutes, an email will notify you when this has completed.
ipharma 2 ltd Companies House Filings - See Documents
| date | description | view/download |
|---|
